A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of IW-1973 in Patients With Type 2 Diabetes With Albuminuria Treated With Renin-Angiotensin System Inhibitors
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2019
At a glance
- Drugs Praliciguat (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Sponsors Ironwood Pharmaceuticals
- 24 Jan 2019 According to an Ironwood Pharmaceuticals media release, this trial has an important milestone update in 2019.
- 06 Aug 2018 According to an Ironwood Pharmaceuticals media release, Topline data from this study are expected in the second half of 2019.
- 02 Nov 2017 Status changed from not yet recruiting to recruiting, according to an Ironwood Pharmaceuticals media release.